Pulmatrix, Inc. Share Price

PULM

US74584P3010

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:22:05 29/07/2026 BST			5-day change	1st Jan Change
1.700 ^USD	+1.19%		+0.59%	-23.77%

05-15	Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Pulmatrix, Inc. announced that it has received $1 million in funding	CI

Analysts' recommendations: Pulmatrix, Inc.

30/03/22	HC Wainwright Adjusts Pulmatrix's Price Target to $10 from $5, Keeps Buy Rating	MT
13/04/21	PULMATRIX : HC Wainwright Adjusts Pulmatrix' Price Target to $5 From $10, Keeps Buy Rating	MT

More recommendations

Press Releases: Pulmatrix, Inc.

05-15	Pulmatrix Announces First Quarter 2026 Financial Results	PR
04-21	Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger	PR
04-13	PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders	BU
03-26	Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan	PR
03-02	Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities	PR

More press releases

Managers and Directors: Pulmatrix, Inc.

Manager	Title	Age	Since
Peter Ludlum CEO	Chief Executive Officer	70	19/07/2024

Director	Title	Age	Since
Richard Batycky BRD	Director/Board Member	58	31/10/2019
Christopher Cabell BRD	Director/Board Member	57	22/06/2020
Todd Bazemore BRD	Director/Board Member	55	30/09/2020

More insiders

Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Companyâ€™s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrixâ€™s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
29/07/26	US$1.700	+1.19%	13,208
28/07/26	US$1.680	-2.89%	11,835
27/07/26	US$1.730	+4.85%	9,127
24/07/26	US$1.650	-6.78%	14,873
23/07/26	US$1.770	+4.73%	20,570

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Cap	6.14M 5.39M 5.03M 4.62M 8.65M 588M 8.86M 59.68M 23.34M 291M 23.04M 22.54M 1.01B	P/E 2024	-2.67x	P/E 2025	-1.58x
Enterprise Value	2.05M 1.8M 1.68M 1.54M 2.89M 196M 2.96M 19.92M 7.79M 97.06M 7.69M 7.52M 336M	EV / Sales 2024	2.05x	EV / Sales 2025	-
Free-Float	99.23%	Yield 2024 *	-	Yield 2025	-

05-15	Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Pulmatrix, Inc. announced that it has received $1 million in funding	CI
04-21	Pulmatrix announces closing of preferred stock transaction as part of planned merger	RE
03-26	Eos SENOLYTIX, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire Pulmatrix, Inc. in a reverse merger transaction.	CI
03-25	Pulmatrix, Inc. announced that it expects to receive $1 million in funding	CI
03-02	Pulmatrix announces termination of prior planned merger and continues pursuit of alternative merger opportunities	RE
02-27	Cullgen Inc. cancelled the acquisition of Pulmatrix, Inc. in a reverse merger transaction.	CI
02-26	Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-18	Pulmatrix and Cullgen continue to pursue merger	RE
16/10/25	Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
16/10/25	Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment	RE
06/08/25	Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
06/08/25	Pulmatrix, Inc. Seeks Potential Divestment of iSPERSE Patent Portfolio	CI

1 day	+1.19%
1 week	+0.59%
1 month	+4.29%
3 months	+37.10%
6 months	-35.11%
Current year	-23.77%

1 week	1.64	1.8
1 month	1.56	1.88
Current year	1.16	3.4
1 year	1.16	5.76
3 years	1.16	10.4
5 years	1.16	20.8
10 years	1.16	1,396

Date	Insider	Type	Main position	Quantity	% Market Cap.
26/01/23	Richard Batycky	Free	Director	1,700	0.0467%
26/01/23	Todd Bazemore	Free	Director	1,700	0.0467%
26/01/23	Margaret Wasilewski	Free	Chief Technology Officer	11,400	0.3133%

Pulmatrix, Inc. Share Price

Stocks

PULM

US74584P3010

Biotechnology & Medical Research

Valuation: Pulmatrix, Inc.

Chart: Pulmatrix, Inc.

Latest news : Pulmatrix, Inc.

Analysts' recommendations: Pulmatrix, Inc.

Press Releases: Pulmatrix, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Pulmatrix, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PULMATRIX, INC.	+1.19%	+0.59%	-67.74%	-35.85%	6.14M
ARGENX SE	+0.47%	+2.27%	+50.78%	+69.72%	55.01B
WUXI APPTEC CO., LTD.	+2.83%	+0.04%	+38.07%	+82.59%	54.24B
BIONTECH SE	+0.13%	+0.66%	-17.08%	-15.10%	23.38B
INSMED INCORPORATED	-0.03%	-2.54%	-1.02%	+370.48%	22.57B
WUXI BIOLOGICS (CAYMAN) INC.	+2.07%	+1.44%	+23.06%	-9.05%	20.19B
GENMAB A/S	-2.15%	-2.30%	+27.27%	-33.01%	17.86B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.14%	-2.72%	+30.26%	+536.72%	15.5B
PHARMAESSENTIA CORPORATION	-3.14%	-8.09%	+160.68%	+292.18%	14.2B
EXELIXIS, INC.	-1.40%	+1.23%	+50.66%	+182.37%	14.2B
Average	-0.19%	-0.62%	+29.49%	+144.11%	23.72B
Weighted average by Cap.	+0.39%	-0.20%	+37.35%	+129.07%

	2024	2025
Net sales	7.81M 6.86M 6.4M 5.88M 11M 748M 11.27M 75.92M 29.69M 370M 29.31M 28.67M 1.28B	-
Net income	-9.56M -8.4M -7.84M -7.2M -13.47M -916M -13.8M -92.97M -36.36M -453M -35.89M -35.11M -1.57B	-5.16M -4.54M -4.23M -3.89M -7.27M -494M -7.45M -50.21M -19.63M -245M -19.38M -18.96M -846M
Net Debt	-9.52M -8.37M -7.81M -7.17M -13.42M -912M -13.75M -92.6M -36.21M -451M -35.75M -34.97M -1.56B	-4.09M -3.59M -3.35M -3.08M -5.76M -392M -5.9M -39.76M -15.55M -194M -15.35M -15.02M -670M